MedPath

Subtypes and Prognostic Factors in Erdheim-Chester Disease

Not Applicable
Recruiting
Conditions
Erdheim-Chester Disease
Registration Number
NCT06317246
Lead Sponsor
Meyer Children's Hospital IRCCS
Brief Summary

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Prevalent and incident patients (adults and pediatric), with histologically confirmed diagnosis of Erdheim-Chester Disease according to the latest diagnostic recommendations;
  • Signing of informed consent for study participation.
Exclusion Criteria
  • Patients for whom clinical and imaging data are not available and for whom it is not possible to retrieve histological samples."

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Clinical characteristics of patients with Erdheim-Chester Disease4 years

Evaluation of clinical characteristics in extreme subtypes of Erdheim-Chester Disease

Prognostic factors of patients with Erdheim-Chester Disease4 years

Evaluation of prognostic factors in extreme subtypes of Erdheim-Chester Disease

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Meyer Children's Hospital IRCCS

🇮🇹

Florence, Firenze, Italy

AOU Parma

🇮🇹

Parma, Italy

Meyer Children's Hospital IRCCS
🇮🇹Florence, Firenze, Italy
Augusto Vaglio
Contact
augusto.vaglio@meyer.it

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.